Amenorrhea from breast cancer therapy--not a matter of dose.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  New England Journal of Medicine

• Publication date

  2010-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMc1009616PMID 21121855
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

  2010cited by this paper

• MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data

  2025cites this paper
• Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group

  2023cites this paper
• Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

  2023cites this paper
• Systemische Therapie von prämenopausalen Patientinnen mit hormonrezeptorpositivem, HER2-negativem Brustkrebs in den Frühstadien – Kontroversen und Standards in der Krankenversorgung

  2023cites this paper
• Role of Ovarian Suppression in Early Premenopausal Breast Cancer.

  2023cites this paper
• Increasing dietary choline attenuates spatial memory deficits resulting from exposure to the chemotherapeutic agents cyclophosphamide and doxorubicin

  2021cites this paper
• Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.

  2021cites this paper
• Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial

  2021cites this paper
• Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.

  2021cites this paper
• Reply to K. Ando et al.

  2021cites this paper
• Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy

  2021cites this paper
• NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy

  2020cites this paper
• Oral GnRH Antagonist Ovarian Suppression After Escape From GnRH Agonist in Breast Cancer Patients.

  2020cites this paper
• Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer

  2020cites this paper
• Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cites this paper
• [Endocrine adjuvant treatment specific features for young breast cancer women].

  2019cites this paper
• Immortal Time Bias in National Cancer Data Base Studies.

  2019cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cites this paper
• Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure

  2019cites this paper
• Precision Medicine in Non Communicable Diseases

  2019cites this paper
• The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study

  2018cites this paper
• Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management

  2018cites this paper
• Medicina baseada na evidência: a propósito de um caso clínico.

  2018cites this paper
• Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant)

  2018cites this paper
• Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy.

  2018cites this paper
• What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?

  2018cites this paper
• Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

  2018cites this paper
• Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update

  2017cites this paper
• Pregnancy in breast cancer survivors : safety and feasibility

  2017cites this paper
• Adjuvant endocrine therapy for premenopausal women: Type and duration.

  2017cites this paper
• Subgroup Analyses and Information from Clinical Trials on Breast Cancer

  2017cites this paper
• Over-treatment in metastatic breast cancer.

  2017cites this paper
• Breast cancer survivors. Early diagnosis – successful treatment – quality of life: multidisciplinary approach

  2016cites this paper
• Are SOFT and TEXT results practice changing and how?

  2016cites this paper
• Evaluación del perfil hormonal en pacientes con cáncer de mama precoz sometidas a hormonoterapia adyuvante

  2016cites this paper
• Treatment Modification in Young Breast Cancer Patients

  2016cites this paper
• Doxorubicin and cyclophosphamide lead to long-lasting impairment of spatial memory in female, but not male mice.

  2016cites this paper
• Unexpected pregnancy during tamoxifen treatment: a case report and review of the literature

  2016cites this paper
• SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study

  2016cites this paper
• Adjuvant ovarian suppression in premenopausal breast cancer.

  2015cites this paper
• Managing breast cancer in younger women: challenges and solutions

  2015cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cites this paper
• The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer.

  2015cites this paper
• Prognostic impact of chemotherapy-induced amenorrhea on premenopausal breast cancer: a meta-analysis of the literature

  2015cites this paper
• Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer

  2015cites this paper
• Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)

  2015cites this paper
• Molecular breast cancer subtypes in Sudan and their impact on management; with emphasis on Luminal sub-type A

  2015cites this paper
• Adjuvant Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer in Premenopausal Patient: Understanding the Data

  2015cites this paper
• Breast Targets Therapy Managing breast cancer in younger women: challenges and solutions

  2015cites this paper
• Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea?

  2014cites this paper
• Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle

  2014cites this paper
• Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.

  2014cites this paper
• Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer.

  2014cites this paper
• Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

  2014cites this paper
• Chemotherapy-Induced Premature Menopause Among Latina Women With Breast Cancer: An Interpretive Description: A Dissertation

  2013influential citation
• Challenges of guarantee-time bias.

  2013cites this paper
• New developments and future directions in systemic therapy.

  2013cites this paper
• Hormonal therapies in young breast cancer patients: when, what and for how long?

  2013cites this paper
• Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes.

  2013cites this paper
• Goserelin with chemotherapy to preserve ovarian function in premenopausal women with early breast cancer : menstruation and pregnancy outcomes

  2012cites this paper
• Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.

  2012cites this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2012cites this paper
• Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer.

  2012cites this paper
• Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy?

  2012cites this paper
• Is adjuvant chemotherapy useful for women with luminal a breast cancer?

  2012cites this paper
• Calpain system protein expression in basal-like and triple-negative invasive breast cancer

  2012cites this paper
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

  2011cites this paper
• Predicting response to cytotoxic drugs--the endocrine part of the story.

  2011cites this paper
• Expanding our therapeutic options: Beta blockers for breast cancer?

  2011cites this paper
• Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in Ovarian Toxicity

  2011cites this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cites this paper
• Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

  2011cites this paper